| Literature DB >> 27157252 |
Aneta Mikulasova1,2,3,4, Jan Smetana1,2, Marketa Wayhelova1,2, Helena Janyskova1, Viera Sandecka5, Zuzana Kufova4,6, Martina Almasi7, Jiri Jarkovsky8, Evzen Gregora9, Petr Kessler10, Marek Wrobel11, Brian A Walker12, Christopher P Wardell12,13, Gareth J Morgan12, Roman Hajek4,6, Petr Kuglik1,2,3.
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a benign condition with an approximate 1% annual risk of symptomatic plasma cell disorder development, mostly to multiple myeloma (MM). We performed genomewide screening of copy-number alterations (CNAs) in 90 MGUS and 33 MM patients using high-density DNA microarrays. We identified CNAs in a smaller proportion of MGUS (65.6%) than in MM (100.0%, P = 1.31 × 10-5 ) and showed median number of CNAs is lower in MGUS (3, range 0-22) than in MM (13, range 4-38, P = 1.82 × 10-10 ). In the MGUS cohort, the most frequent losses were located at 1p (5.6%), 6q (6.7%), 13q (30.0%), 14q (14.4%), 16q (8.9%), 21q (5.6%), and gains at 1q (23.3%), 2p (6.7%), 6p (13.3%), and Xq (7.8%). Hyperdiploidy was detected in 38.9% of MGUS cases, and the most frequent whole chromosome gains were 3 (25.6%), 5 (23.3%), 9 (37.8%), 15 (23.3%), and 19 (32.2%). We also identified CNAs such as 1p, 6q, 8p, 12p, 13q, 16q losses, 1q gain and hypodiploidy, which are potentially associated with an adverse prognosis in MGUS. In summary, we showed that MGUS is similar to MM in that it is a genetically heterogeneous disorder, but overall cytogenetic instability is lower than in MM, which confirms that genetic abnormalities play important role in monoclonal gammopathies.Entities:
Keywords: DNA copy-number changes; DNA microarrays; monoclonal gammopathies; prognosis
Mesh:
Year: 2016 PMID: 27157252 DOI: 10.1111/ejh.12774
Source DB: PubMed Journal: Eur J Haematol ISSN: 0902-4441 Impact factor: 2.997